The Bile Acid Membrane Receptor TGR5 in Cancer: Friend or Foe?

Youchao Qi1,2,3,4, Guozhen Duan2, Dengbang Wei4

  • 1Department of Veterinary Medicine, College of Agriculture and Animal Husbandry, Qinghai University, Xining 810016, China.

Insights

The G-protein-coupled bile acid receptor TGR5 (Gpbar1) influences various cellular processes and is found throughout the body. TGR5 exhibits dual roles in cancer, acting as both a tumor suppressor and an oncogene.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Oncology

Background:

  • G-protein-coupled bile acid receptor (Gpbar1), also known as TGR5, is a membrane receptor activated by bile acids.
  • TGR5 activation triggers multiple signaling pathways, including AKT, NF-κB, ERK1/2, STAT3, cAMP, RhoA, Epac, and TRPA1.
  • This receptor is broadly distributed across various tissues, including the brain, liver, adipose tissue, and digestive system.

Purpose of the Study:

  • To review the dual role of TGR5 in cancer development.
  • To summarize the tumor-suppressing and oncogenic functions of TGR5.
  • To elucidate the mechanisms underlying TGR5's contradictory effects in different cancer cells.

Main Methods:

  • Literature review of recent studies on TGR5.
  • Analysis of TGR5 signaling pathways and their downstream effects.
  • Examination of TGR5 agonist effects (e.g., INT-777, UDCA, TLCA) on cancer cells.

Main Results:

  • TGR5 regulates key cellular functions such as proliferation, inflammation, adhesion, migration, and insulin release.
  • TGR5 activation by agonists shows inconsistent effects on different cancer cells.
  • Evidence suggests both tumor-suppressing and oncogenic activities of TGR5.

Conclusions:

  • TGR5 plays a complex and context-dependent role in cancer.
  • Understanding TGR5's 'friend' and 'foe' features is crucial for targeted cancer therapies.
  • Further research is needed to fully delineate TGR5's mechanisms in tumorigenesis.

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
2.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K